South Korea's MFDS Approves LUMIFY® Eye Drops
/CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY®...
Stay updated with breaking news from Us All Outlet Panel Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY®...
Published: Jan 21, 2021 LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch & Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY ® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea. "The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch + Lomb/International. "LUMIFY will be a we...